Mifepristone’s FDA Regulation Driven by Science: JAMA
A new analysis published in JAMA finds that FDA’s regulation of mifepristone has been driven largely by scientific evidence and internal expert judgment, with limited documented political interference over more than a decade of oversight. The study, released 1/12, examines more than 5,200 pages of internal FDA documents obtained through the Freedom of Information Act and traces the agency’s decision-making on mifepristone — a drug used with misoprostol in the most common abortion regimen in the U.S. — from 2011 through early 2023. The authors conclude that FDA scientists consistently found the drug to be safe and effective, and that regulatory changes were made cautiously, often in response to evolving clinical practice or external events such as the COVID-19 pandemic.
Mifepristone, first approved in 2000, has long been at the center of legal and political battles over abortion access. The FDA has subjected the drug to special safety restrictions for most of its market life, including prescriber certification and limits on how and where it can be dispensed. Since 2011, those restrictions have been administered through a Risk Evaluation and Mitigation Strategy (REMS).
According to the analysis, the agency identified five pivotal moments that shaped the current regulatory framework: conversion to the REMS system in 2011; a formal reevaluation of the REMS in 2013; a sponsor-requested label change approved in 2016; temporary enforcement changes during the Covid-19 emergency; and a comprehensive reassessment of the REMS in late 2021.
Across those periods, FDA scientists repeatedly reaffirmed that serious adverse events associated with mifepristone were rare and that its safety profile remained stable, the study says. Internal reviews cited clinical studies, postmarketing surveillance, and published literature to support that conclusion. The authors report that staff recommendations did not consistently favor either more restrictive or more permissive regulation, undercutting claims that ideological bias drove internal decision-making.
The documents show that FDA scientists supported eliminating the requirement that patients obtain mifepristone in person, concluding that telemedicine and pharmacy dispensing could provide comparable safety protections. That position was adopted temporarily during the pandemic and later incorporated into permanent policy, with the agency replacing in-person dispensing with a pharmacy certification system finalized in 2023.
The study also identifies only two moments where political or leadership intervention appeared to diverge from staff scientists’ views, including the FDA’s decision in 2020 to defend in-person dispensing requirements in court during litigation brought by the American College of Obstetricians and Gynecologists. Even then, the authors found no evidence that such interventions resulted in lasting restrictions beyond what agency scientists ultimately supported.
The findings come as mifepristone remains the subject of ongoing litigation and renewed federal scrutiny following the Supreme Court’s 2024 dismissal of FDA v Alliance for Hippocratic Medicine on procedural grounds. Several states continue to challenge the agency’s authority over the drug, and federal officials have signaled that another review of its safety data is underway.